Surrozen’s (SRZN) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Surrozen (NASDAQ:SRZN) in a research note issued to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $36.00 price objective on the stock, up from their prior price objective of $32.00.

Several other equities research analysts have also issued reports on the stock. Wall Street Zen raised shares of Surrozen to a “sell” rating in a report on Friday, November 28th. Cantor Fitzgerald assumed coverage on Surrozen in a report on Thursday, February 19th. They issued an “overweight” rating and a $40.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Surrozen currently has an average rating of “Moderate Buy” and an average price target of $38.00.

Surrozen Stock Down 1.0%

Shares of NASDAQ SRZN opened at $25.00 on Tuesday. Surrozen has a 12 month low of $5.90 and a 12 month high of $29.59. The business’s 50 day moving average is $24.21 and its two-hundred day moving average is $18.76. The company has a market cap of $214.28 million, a P/E ratio of -0.75 and a beta of 0.53.

Surrozen (NASDAQ:SRZN) last released its earnings results on Monday, March 23rd. The company reported ($23.88) EPS for the quarter, missing the consensus estimate of ($1.29) by ($22.59). Surrozen had a negative net margin of 7,476.67% and a negative return on equity of 1,240.42%. The company had revenue of $0.53 million for the quarter, compared to analyst estimates of $0.66 million. Sell-side analysts expect that Surrozen will post -8.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Surrozen news, major shareholder Group Gp Lp Column III bought 18,052 shares of Surrozen stock in a transaction on Tuesday, January 20th. The shares were purchased at an average cost of $19.60 per share, for a total transaction of $353,819.20. Following the completion of the acquisition, the insider owned 1,016,658 shares in the company, valued at approximately $19,926,496.80. The trade was a 1.81% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Tim Kutzkey bought 18,052 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was acquired at an average cost of $19.60 per share, with a total value of $353,819.20. Following the completion of the purchase, the director owned 1,016,658 shares of the company’s stock, valued at approximately $19,926,496.80. This trade represents a 1.81% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 208,410 shares of company stock worth $4,466,346. Company insiders own 43.50% of the company’s stock.

Hedge Funds Weigh In On Surrozen

Several institutional investors have recently modified their holdings of the business. Stempoint Capital LP increased its stake in Surrozen by 185.1% during the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after purchasing an additional 445,713 shares in the last quarter. Braidwell LP acquired a new stake in Surrozen during the 2nd quarter worth approximately $1,252,000. Stonepine Capital Management LLC lifted its stake in Surrozen by 7.1% in the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after buying an additional 20,247 shares in the last quarter. Armistice Capital LLC acquired a new position in shares of Surrozen in the second quarter valued at approximately $536,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Surrozen in the fourth quarter valued at approximately $414,000. Institutional investors own 66.57% of the company’s stock.

Trending Headlines about Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Cantor Fitzgerald reaffirmed an “overweight” rating and set a $40 price target (implies ~60% upside versus current levels). Article Title
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and raised its price target to $36 from $32 (roughly ~44% upside). Article Title Ticker Report
• Positive Sentiment: Corporate update: Surrozen expects to submit an IND for SZN-8141 in H2 2026, will present retinal vascular research at ARVO 2026, and earned a $5M milestone payment from Boehringer Ingelheim for SZN-413 — all near-term program and partnership milestones that could meaningfully de‑risk upcoming value inflection points. Press Release
• Neutral Sentiment: Short-interest reports for March show anomalous/zero values (0 shares reported, days-to-cover ~0.0) across multiple snapshots — this data appears inconsistent and provides little actionable signal about current short pressure. (No external link provided.)
• Negative Sentiment: Q4 / FY2025 results: Surrozen reported a very large EPS miss — ($23.88) vs. consensus (~($1.29)) — and continued negative margins/ROE; revenue of $0.53M missed expectations. The magnitude of the miss is the primary near-term driver of the stock decline. Earnings Release

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.